SEC Comment Letter for ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA) — Apr 29, 2024

ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: April 29, 2024 · CIK: 0001681682 · Accession: 0000000000-24-004759

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-278842

Date

April 29, 2024

Author

Francois Michelon

Form

UPLOAD

Company

ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)

Letter

United States securities and exchange commission logo April 29, 2024 Francois Michelon Chief Executive Officer ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105-1570 Re:ENDRA Life Sciences Inc. Registration Statement on Form S-1 Filed April 19, 2024 File No. 333-278842 Dear Francois Michelon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Coleman Wombwell, Esq.

Show Raw Text

United States securities and exchange commission logo
April 29, 2024
Francois Michelon
Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
Ann Arbor, MI 48105-1570
Re:ENDRA Life Sciences Inc.
Registration Statement on Form S-1
Filed April 19, 2024
File No. 333-278842
Dear Francois Michelon:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Coleman Wombwell, Esq.

SecProbe.io